The global pediatric vaccine market will likely hit a value of more than $23 billion by 2015, a market analysis shows. GlaxoSmithKline ($GSK) leads the charge with nearly a quarter of the global market. From 2005 to 2011, pediatric vaccines doubled their market share, according to a Renub Research analysis, and will continue to shoot upward. Analysts can attribute much of that growth to blockbuster vaccines such as Pfizer's ($PFE) Prevnar 7 and Prevnar 13, Glaxo's Rotarix and Merck's ($MRK) Rotateq. Pediatric proprietary vaccines will probably lead the vaccine market with just less than 60% market share by 2015, the report says. Some vaccines will slacken the upward trend; boosters and enhanced pediatric vaccines, for example, will slow in terms of growth because of lower margins and the maturity of the markets. But DTP vaccines--diphtheria, tetanus and pertussis--stay on the rise. Pediatric hepatitis and polio vaccines followed behind.
Five major companies dominate the global pediatric vaccines market: Glaxo, Merck, Sanofi Pasteur, Pfizer and Novartis ($NVS). Glaxo sits a length ahead, largely thanks to its influenza products Fluvarix and Hiberix. Vaccines are available for 20 different diseases, 10 of which are recommended for use in all children in the United States. Despite the gamut, though, 2 million children die each year from diseases that could have been prevented by those vaccines. Unsurprisingly, many of the deaths occur in poor countries.
Vaccine Exemption Forms